期刊文献+

STI571耐药白血病细胞系的建立及其生物学特性初步研究 被引量:1

Establishment of K562 Cell Lines Resistant to STI571 and a Preliminary Biological Study
下载PDF
导出
摘要 为了探讨STI5 71耐药机制和体外诱导建立甲磺酸伊马替尼 (imatinibmesylate ,又称STI5 71)耐药的白血病细胞系 ,采用STI5 71递增给药的方法诱导裸鼠高致瘤性人慢粒红白血病变细胞系K5 6 2 n和多药耐药细胞系K5 6 2 n VCR对STI5 71耐药 ,比较它们与各自亲本细胞系间基本生物学特性的异同。结果显示 ,建立多药耐药基础上对STI5 71耐药的白血病细胞亚系K5 6 2 n VCR STI,对STI5 71耐药倍数为 2 3.4 1,对长春新碱 (VCR)耐药倍数为 6 6 2 .2 6 ,对高三尖杉酯碱 (HHT)具有交叉耐药性。K5 6 2 n经STI5 71诱导后对多种药物耐受性有所提高 ,命名为K5 6 2 n STI。K5 6 2 n STI和K5 6 2 n VCR STI细胞内DNR积聚量分别为 33.2 4和 18.76 ,低于各自亲本细胞系。K5 6 2 n STI与K5 6 2 n VCR STI均检测到mdr 1基因的mRNA转录。K5 6 2 n STI和K5 6 2 n VCR STI与亲本细胞系相比 ,倍增时间延长 ,增殖指数增高。结论 :体外小剂量STI5 71递增给药的方法能够提高K5 6 2 n细胞系对STI5 71的耐受性 ,同时mdr 1基因表达阳性 ,表现一定程度的多药耐受 ,提示STI5 71耐药机制与多药耐药机制之间可能存在相关性。由于K5 6 2 n为裸鼠高致瘤的人白血病细胞系 ,K5 6 2 n STI和K5 6 2 n VCR STI5 To produce leukemic STI571-resistant cell lines and to explore the mole cular mechanism of STI571-resistance, cell lines K562-n and K562-n/VCR were induced by exposing cells to gradually increasing STI571 concentration of culture medium to have STI571-resistance and major biological characteristics between th ese subclones and the parent cells were compared. The results showed that a STI5 71-resistant cell line based on multidrug-resistance was established,which exhibited 23.41-fold re sistance to STI571, 662.26-fold resistance to VCR and cross-resistance to HHT. K 562-n/STI was generated from K562-n and had some characteristics of MDR. The i nt racellular accumulation of DNR in K562-n/STI and K562-n/VCR/STI were 33.24 and 1 8.76 respectively. Transcription of mdr-1 gene in both K562-n/STI and K562-n/ V CR/STI was positive. Cell doubling time of K562-n/STI and K562-n/VCR/STI was s ignif icantly longer than that in their parent cells (P<0.05). And proliferation i ndex was also highe r than that in parent cells (P<0.05). It is conclusion that the tolerance of K562-n cells to STI571 can be augmented by adding low-dose of STI571 into t he culture medium repeatedly. K562-n/STIs expressed MDR at som e extent, and transcription of mdr-1 gene in K562-n/STIs was positive. As K562-n is a cell line used to develope human leukemia in nude mice, K562-n/ ST I and K562-n/VCR/STI 571 will contribute to the study of mechanism of STI571-r esistance as in vitro and in vivo exprimental models.
出处 《中国实验血液学杂志》 CAS CSCD 2004年第5期584-589,共6页 Journal of Experimental Hematology
关键词 多药耐药 STI571 慢性髓性白血病细胞系 细胞培养 multidrug-resistance STI571 chronic myeloid leukemia cel l line cell culture
  • 相关文献

参考文献10

  • 1许小平,丁训杰,阎影,史剑慧,程文英.裸小鼠高成瘤性人白血病细胞系的建立及其生物学特性观察[J].中华血液学杂志,1996,17(3):142-145. 被引量:27
  • 2Von-Bubnoff N, Schneller F, Peschel C, et al. BCR/ABL gene mutations in relation to clinical resistance of philadelphia-chromosome positive ( + ) leukemia to STI571 :a prospective study. Lancet,2002; 359: 487- 491
  • 3Sawyers CL. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Semin-Hematol, 2001; 38:15-21
  • 4Fang G, Kim CN, Perkins CL, et al. CGP57148B(STI571) in duces differentiation and apoptosis and ssensitizes BCR/ABL-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood,2000; 96:2246 - 2253
  • 5Keeshan K, Mills KI,Couer TG, et al. Elevated bcr/abl espression levels are sufficient for a haematopoietic cells line to acquire a drugresistant phenotype. Leukenia,2001; 15:1823-1833
  • 6Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor ST1571 in BCR/ABL-transformed hematopoietic cell lines. Blood, 2000; 95:3498 - 3505
  • 7Marks DC, Belov L, Davey MW, et al. The MTT viability assay for cytotoxicity testing in multidrug resistant human leukemic cells.LeukRes, 1992; 16:1165-1173
  • 8Gorre ME, Mohammed M, Ellwood K, et al. C linical resistance to STI-571 cancer therapy caused by BCR/ABL gene mutation or amplification. Science,2001; 293:876-880
  • 9Hofmann WK, Jones LC, Lemp NA, et al. Ph( + ) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR/ABL gene mutation. Blood,2002; 99:1860-1862
  • 10陈莉,许小平,王健民,吕书晴,居小萍,周虹,黄正霞.裸鼠高成瘤性多药耐药白血病细胞系的建立及其生物学特性研究[J].第二军医大学学报,2004,25(5):507-511. 被引量:9

二级参考文献10

  • 1许小平,丁训杰,阎影,史剑慧,程文英.裸小鼠高成瘤性人白血病细胞系的建立及其生物学特性观察[J].中华血液学杂志,1996,17(3):142-145. 被引量:27
  • 2应红光,中华血液学杂志,1994年,15卷,239页
  • 3褚建新,中华血液学杂志,1989年,10卷,79页
  • 4Ding BC,Witt TL,Hukku B,et al. Association of deletions and translocation of the reduced folate carrier gene with profound loss of gene expression in methotrexate-resistant K562 human erythroleukemia cells [J]. Biochem Pharmacol, 2001,61 (6):665-675.
  • 5Melixetian MB, Beryozkina EV, Pavlenko MA, et al. Altered expression of DNA-topoisomerase Ⅱα is associated with increased rate of spontaneous polyploidization in etoposide resistant K562 cells[J]. Leuk Res,2000,24(10) :831-837.
  • 6Dumontet C,Fabianowska K,Mantincic D,et al. Common resistance mechanisms to nucleoside analogues in variants of the human erythroleukemic line K562[J]. Br J Haematol, 1999,106(1) :78-85.
  • 7Grinchuk TM,Pavlenko MA,Lipskaia LA,et al. Resistance to adriamycin in human chronic promyeloleukemia line K562 correlates with directed genome destabilization-amplification of MDR1 gene and nonrandom changes in karyotype structure [J]. Tsitologiia , 1998
  • 8Zhou DC,Ramond S,Viguie F,et al. Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines[J]. Int J Cancer, 1996,65 (3): 365-371.
  • 9许小平,吕书晴,史剑慧,许荣.裸鼠高致瘤性人白血病细胞系染色体核型分析[J].第二军医大学学报,2002,23(9):955-958. 被引量:3
  • 10吕书晴,许小平,王健民,周虹,居小萍.裸小鼠高致瘤性K562-n细胞系的生物学特性研究[J].肿瘤,2002,22(6):459-462. 被引量:6

共引文献31

同被引文献15

  • 1齐静,彭晖,顾振纶,梁中琴,杨纯正.伊马替尼耐药的K562细胞系的建立及其生物学特性研究[J].中华血液学杂志,2004,25(6):337-341. 被引量:20
  • 2Urasaki Y,Laco GS,Pourquier P,et al.Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line[J].Cancer Res,2001,61(5):1964-1969.
  • 3Xu JM,Azzariti A,Colucci G,et al.The effect of gefitinib (Iressa,ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines[J].Cancer Chemother Pharmacol,2003,52(6):442-448.
  • 4Toda D,Ota T,Tsukuda K,et al.Gefitinib decreases the synthesis of matrix metalloproteinase and the adhesion to extracellular matrix proteins of colon cancer cells[J].Anticancer Res.2006,26(1A):129-134.
  • 5Jones HE,Goddard L,Gee JMW,et al.Insulin-like growth factor-1 receptor signaling and acquired resistance to gefitinib (ZD1839,Iressa) in human breast and prostate cancer cells[J].Endocr Relat Cancer.2004,11(4):793-814.
  • 6Koizumi F,Shimoyama T,Taguchi F,et al.Establishment of a human non-small cell lung cancer cell line resistant to gefitinib[J].Int J Cancer,2005,116(1):36-44.
  • 7Kobayashi S,Boggon TJ,Dayaram T,et al.EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2005,352(8):786-792.
  • 8Pao W,Miller VA,Politi KA,et al.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J].PLOS,2005,2(3):73.
  • 9Riely GJ,Politi KA,Miller VA,et al.Update on epidermal growth factor receptor mutations in non-small cell lung cancer[J].Clin Cancer Res,2006,12(24):7232-7241.
  • 10She OB,Solit D,Basso A,et al.Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling[J].Clin Cancer Res,2003,9(12):4340-4346.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部